[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1113439T1 - Ενωση αζολιου - Google Patents

Ενωση αζολιου

Info

Publication number
CY1113439T1
CY1113439T1 CY20121101178T CY121101178T CY1113439T1 CY 1113439 T1 CY1113439 T1 CY 1113439T1 CY 20121101178 T CY20121101178 T CY 20121101178T CY 121101178 T CY121101178 T CY 121101178T CY 1113439 T1 CY1113439 T1 CY 1113439T1
Authority
CY
Cyprus
Prior art keywords
neuropathic pain
compound
activity
present
faah
Prior art date
Application number
CY20121101178T
Other languages
English (en)
Inventor
Satoshi Aoki
Ryosuke Munakata
Noriyuki Kawano
Kiyohiro Samizu
Hiromasa Oka
Takahiro Ishii
Takashi Sugane
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY1113439T1 publication Critical patent/CY1113439T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

[Προβλήματα] Παρέχεται ένωση που είναι χρήσιμη ως δραστικό συστατικό φαρμακευτικής σύνθεσης για θεραπεία νευροπαθητικού πόνου. [Μέσα για επίλυση] Οι παρόντες εφευρέτες έχουν πραγματοποιήσει εκτενείς μελέτες σε ενώσεις που έχουν ανασταλτική δραστικότητα FAAH και ως αποτέλεσμα, έχουν βρει ότι ένωση αζολίου, υποκατεστημένη με Ν-(πυριδιν-3-υλ)οξ-υκαρβονυλ-πιπεριδιν-4-ύλ ομάδα και φαινύλ ομάδα ή φαρμακευτικώς αποδεκτό άλας αυτής έχει εξαιρετική ανασταλτική δραστικότητα FAAH, ολοκληρώνοντας έτσι την παρούσα εφεύρεση. Επιβεβαιώνεται ότι η ένωση της παρούσας εφεύρεσης έχει ανασταλτική δραστικότητα FAAH και κατά της αλλοδυνίας δράση σε μοντέλα αρουραίου με νευροπαθητικό πόνο και έτσι είναι χρήσιμη ως παράγων για πρόληψη ή/και παράγων για θεραπεία νευροπαθητικού πόνου.
CY20121101178T 2008-07-14 2012-12-03 Ενωση αζολιου CY1113439T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008182251 2008-07-14
EP09797891A EP2308869B1 (en) 2008-07-14 2009-07-13 Azole compound

Publications (1)

Publication Number Publication Date
CY1113439T1 true CY1113439T1 (el) 2016-06-22

Family

ID=41550369

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101178T CY1113439T1 (el) 2008-07-14 2012-12-03 Ενωση αζολιου

Country Status (21)

Country Link
US (1) US8207199B2 (el)
EP (1) EP2308869B1 (el)
JP (1) JP5423675B2 (el)
KR (1) KR101566051B1 (el)
CN (1) CN102099354B (el)
AU (1) AU2009273105B2 (el)
BR (1) BRPI0915876B1 (el)
CA (1) CA2730793C (el)
CY (1) CY1113439T1 (el)
DK (1) DK2308869T3 (el)
ES (1) ES2393245T3 (el)
HR (1) HRP20120969T1 (el)
IL (1) IL210226A (el)
MX (1) MX2011000415A (el)
PL (1) PL2308869T3 (el)
PT (1) PT2308869E (el)
RU (1) RU2493154C2 (el)
SI (1) SI2308869T1 (el)
TW (1) TWI434842B (el)
WO (1) WO2010007966A1 (el)
ZA (1) ZA201100139B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JP2013147430A (ja) * 2010-04-28 2013-08-01 Astellas Pharma Inc 夜間頻尿の予防又は治療剤
FR2974365B1 (fr) 2011-04-20 2017-08-25 Centre Nat De La Rech Scient (C N R S) 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques
DE102012018115A1 (de) 2012-09-13 2014-03-13 Matthias Lehr Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase
KR20150064098A (ko) * 2012-10-02 2015-06-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 이미다졸 유도체
DE102013016573A1 (de) 2013-10-04 2015-04-09 Matthias Lehr 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung
CN106632260B (zh) * 2016-09-29 2019-04-26 上海天慈生物谷生物工程有限公司 一种小分子激酶抑制剂的制备方法
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
WO2019084157A1 (en) * 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
CN108409727A (zh) * 2017-10-25 2018-08-17 巨德峰 一种脂肪酰胺水解酶抑制剂及其制备方法
MA52365A (fr) 2018-04-25 2021-03-03 Yumanity Therapeutics Inc Composés et leurs utilisations
CN108912112A (zh) * 2018-08-14 2018-11-30 李敬敬 一种化合物、制备方法以及其在治疗疼痛中的应用
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69722360T2 (de) * 1996-06-29 2003-11-27 Samjin Pharm, Co. Piperazin-derivate und verfahren zu ihrer herstellung
AU2002351732A1 (en) 2001-12-14 2003-06-30 Novo Nordisk A/S Compositions decreasing activity of hormone-sensitive lipase
WO2003065989A2 (en) 2002-02-08 2003-08-14 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
WO2004033422A2 (en) 2002-10-07 2004-04-22 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
ES2433290T3 (es) 2005-02-17 2013-12-10 Astellas Pharma Inc. Derivados de piperazina para el tratamiento de la incontinencia urinaria y el dolor
GB2424955B (en) 2005-04-09 2008-07-16 Siemens Ag Flow meter with conductive coating
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
JPWO2007020888A1 (ja) 2005-08-12 2009-02-26 武田薬品工業株式会社 脳・神経細胞保護剤および睡眠障害治療薬

Also Published As

Publication number Publication date
CA2730793C (en) 2014-12-30
ES2393245T3 (es) 2012-12-19
PL2308869T3 (pl) 2013-02-28
JP5423675B2 (ja) 2014-02-19
TW201014840A (en) 2010-04-16
CN102099354B (zh) 2013-07-10
RU2493154C2 (ru) 2013-09-20
CA2730793A1 (en) 2010-01-21
AU2009273105B2 (en) 2013-09-05
TWI434842B (zh) 2014-04-21
EP2308869B1 (en) 2012-09-19
HRP20120969T1 (hr) 2012-12-31
US20110118311A1 (en) 2011-05-19
EP2308869A4 (en) 2011-07-27
CN102099354A (zh) 2011-06-15
AU2009273105A1 (en) 2010-01-21
SI2308869T1 (sl) 2012-12-31
RU2011105151A (ru) 2012-08-20
US8207199B2 (en) 2012-06-26
DK2308869T3 (da) 2012-10-08
EP2308869A1 (en) 2011-04-13
MX2011000415A (es) 2011-03-15
KR101566051B1 (ko) 2015-11-04
IL210226A (en) 2014-07-31
BRPI0915876B1 (pt) 2019-07-09
BRPI0915876A2 (pt) 2015-11-03
IL210226A0 (en) 2011-03-31
PT2308869E (pt) 2012-12-06
JPWO2010007966A1 (ja) 2012-01-05
KR20110038671A (ko) 2011-04-14
ZA201100139B (en) 2012-03-28
WO2010007966A1 (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
CY1113439T1 (el) Ενωση αζολιου
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
CY1124652T1 (el) Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
EA201070786A1 (ru) Бензофуропиримидиноны
GEP201706611B (en) Amido compounds and their use as pharmaceuticals
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
NO20075258L (no) Vannfrie krystallinske former av N-(1-(2-etoksyetyl)-5-(N-etyl-N-metylamino)-7-(4-metylpyndin-2-yl-amino)-1H-pyrazolo(4,3-d)pyrimidin-3-carbonyl)metansulfonamid
EA201170441A1 (ru) Терапевтические противовирусные пептиды
EA201170872A1 (ru) Ингибиторы протеинкиназы
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
WO2008048981A3 (en) Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
CY1119999T1 (el) Καινοτομος συνθεση για τη θεραπευτικη αντιμετωπιση της κυστικης ινωσης
EA200801199A1 (ru) Ингибиторы киназы
DK2173749T3 (da) 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamidderivater og beslægtede forbindelser som antisvampemidler
EA202191286A1 (ru) Ингибитор 15-pgdh
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα